Steven Steinhubl, MD, Joins The Medicines Company as Global Vice President, Thrombosis

The Medicines Company (NASDAQ: MDCO) today announced that Dr.
Steven Steinhubl has joined the Company as Global Vice President,
Thrombosis. Dr. Steinhubl will be responsible for the development
programs for both cangrelor, an investigational antiplatelet agent,
and Angiox(R) (bivalirudin) from the Company´s European headquarters
in Zurich, Switzerland. His appointment marks the Company´s first
global leadership position based outside of the United States.

"It is exciting to be a part of driving The Medicines Company´s
growth into a global organization," said Dr. Steinhubl. "Despite all
the advances in acute care for heart disease, we still have a critical
need to further improve outcomes for these patients. My experience as
a clinician and cardiovascular researcher provides me with unique
understanding to oversee development of cangrelor and other important
therapies that can address the needs of acute cardiac care patients."

Dr. Steinhubl is a leading interventional cardiologist and
cardiovascular researcher. Prior to joining the Company, Dr. Steinhubl
was an Associate Professor of Medicine and the Director of the
Cardiovascular Education and Clinical Research at the University of
Kentucky in Lexington for the past 4 years. Dr. Steinhubl has been the
principle investigator and served on the Steering Committees for
numerous large clinical trials including CREDO, STEEPLE, STRADIVARIUS,
SYNERGY, and CHARISMA. His research activities have led to the
publication of over 100 peer-reviewed manuscripts as well as numerous
book chapters, and abstracts.

"Dr. Steinhubl´s real-world experience in acute cardiac care and
international study experience will be invaluable to ensure we fully
maximize the development programs for cangrelor and Angiox globally,"
said Clive Meanwell, Chairman and CEO of The Medicines Company.

MDCO-G

About The Medicines Company

The Medicines Company (NASDAQ: MDCO) is committed to delivering
innovative, cost-effective acute care products in the worldwide
hospital marketplace. The Company markets Angiomax(R) / Angiox(R)
(bivalirudin) in the United States and other countries for use in
patients undergoing coronary angioplasty, a procedure to clear
restricted blood flow in arteries around the heart. The Company also
has two products in late-stage development, Cleviprex(TM) (clevidipine
butyrate injectable emulsion) and cangrelor. The Company´s website is
www.themedicinescompany.com.

Statements contained in this press release about The Medicines
Company that are not purely historical, and all other statements that
are not purely historical, may be deemed to be forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Without limiting the
foregoing, the words "believes," "anticipates" and "expects" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the Company´s actual results,
levels of activity, performance or achievements to be materially
different from those expressed or implied by these forward-looking
statements. Important factors that may cause or contribute to such
differences include whether the Company´s products will advance in the
clinical trials process on a timely basis or at all, whether clinical
trial results will warrant submission of applications for regulatory
approval, whether the Company will be able to obtain regulatory
approvals, whether physicians, patients and other key decision-makers
will accept clinical trial results, and such other factors as are set
forth in the risk factors detailed from time to time in the Company´s
periodic reports and registration statements filed with the Securities
and Exchange Commission including, without limitation, the risk
factors detailed in the Company´s Quarterly Report on Form 10-Q filed
on November 8, 2007, which are incorporated herein by reference. The
Company specifically disclaims any obligation to update these
forward-looking statements.